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Abstract PI31 is a previously described inhibitor of 20S
proteasomes. Using recombinant PI31 we have analyzed its
effect on proteasomal hydrolyzing activity of short fluorogenic
substrates and of a synthetic 40-mer polypeptide. In addition, we
investigated its influence on the activation of 20S proteasome by
the proteasome activator PA28. PI31 inhibits polypeptide
degradation already at concentrations which only partially
inhibit fluorogenic substrate turnover and immunosubunits do
not influence the PI31 binding affinity. Furthermore our data
demonstrate that PI31 is a potent competitor of PA28-mediated
activation.
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1. Introduction
The proteasome is considered to be the central protease
complex and major mediator of controlled proteolysis in the
cytosol of eukaryotic and prokaryotic cells and in archaebac-
teria. The proteasome consists of a catalytically active core
complex, the 20S, which is controlled by a variety of speci¢c
regulatory proteins including activators, inhibitors, and mod-
ulators (for review see [1]). While the function of the protea-
some is increasingly well understood ^ for example its role in
cell cycle progression, degradation of transcription factors or
in the selective proteolysis of antigens for presentation by
MHC class I molecules (for review see [2]) ^ the in£uence of
regulatory complexes on proteasomal activity is not yet clear.
The 20S core particle consists of four rings each containing
seven subunits. The outer terminal rings are built of alpha
subunits, whereas the inner two rings contain the catalytically
active beta subunits. While in archeae both the alpha subunits
and the beta subunits are encoded by one single gene each [3],
in eukaryotes each of the seven subunits is encoded by its own
speci¢c gene. Of the seven beta subunits only three (delta/L2,
MC14/L1 and MB1/L5) display catalytic activity.
DeMartino and coworkers performed a biochemical screen
to identify complexes which could modify the activity of the
20S proteasome. They found two activators, termed PA28 [4]
or 11S regulator [5] and PA700 [6] or 19S regulator [7]. These
activators bind to the terminal rings of the 20S core particle to
form proteasome-regulator complexes, and greatly increase
proteolytic activity towards short £uorogenic substrates.
PA700 is a complex of 700 kDa composed of at least 16 sub-
units, which are organized in two distinguishable subcom-
plexes, the base and the lid. The base consists of six ATPases
which bind to the proteasome via an ATP-dependent mecha-
nism, and displays unfoldase activity, as shown recently by
our group [8]. The lid is connected to the base most likely
by one single subunit and has the ability to bind poly-ubiq-
uitin conjugates. The complex formed by the 20S proteasomal
core complex and PA700 is called the 26S proteasome. Reg-
ulation of proteolysis by 26S proteasomes is considered to
occur predominantly at the level of ubiquitin conjugation
onto substrates, which thereby are targeted towards the lid
and for degradation (for review see [9]).
The proteasomal function is modulated by IFNQ through
the induction of homologues of the three catalytically active
20S proteasome beta subunits, the so-called immunosubunits.
These homologues are preferentially incorporated and change
the enzymatic activity of the 20S proteasome, resulting in
altered cleavage site usage in viral and self proteins that en-
compass MHC class I binding peptides [10].
The other activating complex, PA28, is a high-a⁄nity acti-
vator of the proteasome’s multiple peptidase activities. PA28
is found in mammalian cells, at relatively low levels, however,
it is strongly inducible by IFNQ. It binds to the 20S protea-
some and has been shown to modulate the catalytic activity of
the 20S proteasome complex in vitro to favour antigenic pep-
tide production [11,12]. Furthermore, the overexpression of
PA28 in mouse cells enhances the cell surface presentation
of speci¢c viral CTL epitopes [13].
In the original screen for complexes that modulate 20S
proteasome activity, the group of DeMartino identi¢ed anoth-
er regulatory protein, the proteasome inhibitor PI31 [14].
While the physiological role of this protein is not yet under-
stood, important functions in for example modulating the role
of PA28 could be hypothesized. Therefore, we produced re-
combinant PI31 and tested the in£uence of this protein on the
enzymatic activity of di¡erent proteasome populations and on
PA28-e¡ected proteasome activation.
2. Materials and methods
2.1. Generation of mouse PI31 expression construct
Murine PI31 was cloned by RT-PCR (reverse transcriptase-
polymerase chain reaction) using mouse ¢broblast mRNA as a tem-
plate and oligonucleotide primers from the 5P UTR and 3P UTR of
PI31, with the sequences GCTTTCTGCATAGTCCCCTCC and
CAAGAATACTGACGCTGATG, respectively. The PCR was per-
formed with PFU-polymerase (Promega, Madison, WI, USA) in
30 cycles using an annealing temperature of 55‡C.
The product was cloned into the Topo-cloning vector (Invitrogen,
Groningen, The Netherlands) and sequenced with an ABI-PRISM
sequencer. The obtained cDNA was cloned into the 4T3pGex gluta-
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thione S-transferase fusion vector (CLONTECH, Palo Alto, CA,
USA) using the oligonucleotide primers CCCGAATTCCATGG-
CGGGTCTCGAGGTTCTC at the 5P and GATGCGGCCGCTCA-
CAGGTACATGTCATCGTAG at the 3P end. The resulting recombi-
nant protein has three additional amino acids (i.e. GlySerPro) after
the thrombin cleavage at the N-terminus.
2.2. Expression of the recombinant PI31
The recombinant mPI31/glutathione S-transferase fusion protein
was expressed in Escherichia coli strain DH5K according to standard
procedures. Brie£y, bacteria were grown in the presence of 2% glucose
at 37‡C until logarithmic phase (OD600 0.6) and then shifted to 30‡C.
IPTG was added to an end concentration of 100 mM. Cultures were
harvested, resuspended in ice cold lysis bu¡er (50 mM Tris (pH 7.5)
and 150 mM NaCl) with PMSF and lysed with the French Press.
Lysates were cleared and loaded on a gluthatione column (Sigma,
St. Louis, MO, USA) at 4‡C, which was extensively washed with PBS
and then incubated with 10 U biotinylated thrombin (Novagen, Mad-
ison, WI, USA) in thrombin cleavage bu¡er (20 mM Tris-HCl, pH
8.4, 150 mM NaCl, 2.5 mM CaCl2) at 4‡C overnight. recPI31 was
recovered from the column with the streptavidin agarose bound
thrombin (Novagen) and pelleted. The supernatant was loaded onto
a Resource Q FPLC column (Pharmacia, Upsala, Sweden) in 100 mM
Tris (pH 7.2) which was then eluted with a linear gradient from
100 mM to 500 mM NaCl. Recombinant mPI31 eluted at a salt
concentration of 160 mM NaCl.
2.3. 20S proteasome preparations
20S proteasomes were puri¢ed according to standard procedures
[10].
2.4. Fluorogenic peptide digestion assays
20S proteasome activity assays with short £uorogenic oligopeptides
and the in vitro polypeptide digestions were performed as described
[10].
2.5. PA28 complex isolation
PA28 was isolated from mouse embryonal cells which express
PA28K and L at high levels from a Tet-regulated promoter (van
Hall and Sijts, in preparation). 6U106 cells cultured for 3 days in
the absence of Tet, to induce PA28 expression, were harvested, lysed
with 0.1% Triton lysis bu¡er and three times freeze/thawed. Lysates
were applied to a 10^40% glycerol gradient, which was centrifuged for
15.49 h at 40 000 rpm at 4‡C. Fractions of 600 Wl were collected and
tested for their capacity to activate isolated 20S proteasome as de-
scribed [10]. Fraction 9 was chosen for further experiments, since it
Fig. 1. Alignment of the human and the murine PI31 protein sequences.
Fig. 2. PI31 is an e⁄cient inhibitor of 20S proteasome activity. Peptide cleavage activity was assayed by incubating speci¢c substrates with 200
ng puri¢ed 20S proteasome in the presence of various concentrations of PI31 in a volume of 100 Wl for 60 min at 37‡C. Release of the £uores-
cent groups was measured with a spectro£uorometer at 390 nm excitation/460 nm emission for Suc-LLVY-AMC (a) and Bz-VGR-AMC (c) or
at 355 nm excitation/405 nm emission for Z-LLE-LNa (b), and plotted on the y axis. Mean values of duplicate wells are plotted.
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strongly activated the puri¢ed 20S proteasome and did not exhibit
proteolytic activity in the absence of 20S proteasome. The PA28 con-
centration in this fraction was estimated by Western blot analysis with
titrated standard concentrations of recombinant PA28L protein.
3. Results
3.1. Cloning of mouse PI31
To investigate the in£uence of the proteasome inhibitor
PI31 on proteasome function we cloned the protein coding
region of the mouse PI31 cDNA to express PI31 as a GST
fusion protein.
To identify the mouse homologue of the human PI31 the
mouse EST databases of the GenBank were screened with
sequence fragments of the published human PI31 protein (ac-
cession number: D88378). Received EST sequences were used
to select oligonucleotide primers located in the predicted
3P UTR and the 5P UTR of the mouse PI31 cDNA. PI31
cDNA was cloned by RT-PCR using polyT-RNA of BALB/
c mouse ¢broblast cells (see Section 2). The deduced mPI31
amino acid sequence has the same length as hPI31 and dis-
plays 83% identity (Fig. 1). The C-terminus of PI31, which is
unusually rich in proline residues can be separated into a
strongly conserved region (residues 204 to 271; two conserva-
tive changes in 67 amino acids) and a less well conserved
region (residues 150 to 203; 17 out of 54 amino acids are
non-conservatively exchanged). The remaining protein regions
are relatively well conserved (28 amino acid exchanges in a
total of 149 residues) and, according to structure prediction
programs (Preditor EMBL, Heidelberg, Germany), maintains
a dominant helical structure, which is also predicted for the
human PI31.
3.2. Expression of PI31 as a GST fusion protein
mPI31 cDNA was cloned into a GST expression vector and
expressed in E. coli. The secreted recombinant protein was
bound to a glutathione column, PI31 was cleaved o¡ with
thrombin (see Section 2) and puri¢ed by FPLC using a Re-
source Q column. The protein was tested for its capacity to
inhibit 20S activity by monitoring the hydrolysis of short £u-
orogenic peptide substrates. As shown in Fig. 2, cleavage after
tyrosine (chymotrypsin-like or ChT-l activity) and after gluta-
mic acid (peptidyl-glutamyl hydrolyzing or PGPH activity)
were inhibited by PI31 whereas cleavage after arginine (tryp-
sin-like or T-l activity) was less sensitive to inhibition. While a
substantial overall reduction in activity was achieved, PI31,
even when added at relatively high concentrations, failed to
Fig. 3. PI31 inhibits the digestion of a synthetic hepatitis B virus
40-mer polypeptide. 660 ng peptide was incubated in a volume of
100 Wl for 8 h at 37‡C without proteasomes (A) and with 1 Wg puri-
¢ed 20S proteasome in the absence (B) and in the presence (C) of
8 Wg PI31. Digestion products were separated by HPLC.
Fig. 4. PI31 inhibits 20S proteasome with the same kinetics regard-
less of their subunit composition. 20S proteasomes were puri¢ed
from MEC217 cells grown in the presence or absence of 10 ng/ml
or 400 ng/ml tetracycline. The puri¢ed proteasomes had either an
almost complete, a 55% or 0%, exchange of constitutive for immu-
nosubunits, respectively. Peptide cleavage activity of these protea-
somes in the presence of various concentrations of PI31 were as-
sayed by incubating Suc-LLVY-AMC with 200 ng puri¢ed 20S
proteasome as described in Fig. 2a.
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abrogate 20S activity completely (Fig. 2). In contrast, already
concentrations of recombinant PI31, which had minor e¡ects
on cleavage of short £uorogenic peptides, in particular on
such as Bz-VGR-AMC, inhibited the digestion of polypep-
tides by the 20S proteasome completely (Fig. 3). Altogether,
we conclude that the activity of recombinant mPI31 is
comparable to that described for the puri¢ed bovine PI31 [14].
3.3. PI31 inhibits activity of both constitutive and
immunoproteasomes
To test whether inhibition by PI31 is in£uenced by changes
in the subunit composition of the 20S proteasome complex,
puri¢ed 20S proteasomes containing either the constitutive or
the IFNQ-inducible immunosubunits were tested for their spe-
ci¢c inhibition kinetics. Proteasomes used were puri¢ed from
mouse ¢broblast B8 cells which show a roughly 50% exchange
of constitutive for immunosubunits upon culture in the pres-
ence of INFQ, and from mouse embryonal MEC217 cells
which express the immunosubunits in an inducible and titrat-
able fashion from a tetracycline (Tet)-regulated promoter
(Sijts and Kloetzel, in preparation). Testing the activity of
the puri¢ed proteasome populations against di¡erent short
£uorogenic peptide substrates, we found that the incorpora-
tion of the immunosubunits reduced cleavage of the Suc-
LLVY-AMC peptide as described previously [10,11]. Titrating
PI31 into the experiments showed that the kinetics of inhi-
bition were identical for the di¡erent proteasome populations
tested (Fig. 4). Therefore, we conclude that PI31 acts as a
general inhibitor of 20S activity and that its function is not
a¡ected by proteasomal subunit composition.
3.4. PI31 alters 20S activity but not speci¢city
We previously reported that the INFQ-induced proteasome
activator PA28 modi¢es the cleavage mechanism of protea-
somes such as to promote coordinated double cleavage events
in certain polypeptide substrates [12]. To determine whether
PI31 alters the quality of proteasome-mediated cleavages, we
digested synthetic polypeptides with puri¢ed 20S proteasome
of uninduced MEC217 cells in the absence or presence of PI31
at a concentration that reduces cleavage activity to 15%, as
measured with £uorogenic Suc-LLVY-AMC substrate. While
PI31 diminished polypeptide substrate turnover drastically, we
did not detect any changes in the quality of the digestion
products generated (Fig. 5). Higher concentrations of PI31
abolished polypeptide degradation completely (Fig. 3). These
data indicate that PI31 inhibits 20S activity without in£uenc-
ing cleavage speci¢city.
3.5. Competition between PI31 and PA28
PA28 activates proteasomes in vitro and facilitates protea-
some-mediated liberation of MHC class I binding peptides
from viral substrates [11]. We analyzed whether PI31 can
compete PA28 function. PA28 was isolated from mouse em-
bryonal cells which express both PA28K and PA28L at high
levels, from a Tet-regulated promoter (van Hall and Sijts, in
preparation). Cell lysates of induced cells were applied to a
glycerol gradient and fractions 6 to 11 were identi¢ed as 20S
activating fractions containing PA28 complexes in peptide di-
gestion assays and by Western analysis using PA28-speci¢c
antisera (see Section 2). The same fractions of uninduced
MEC cells that did barely express PA28 did not activate
20S activity, excluding the possibility that the observed en-
hanced substrate cleavage was mediated by putative other
proteases present in the selected fractions.
To test the in£uence of PI31 on PA28-mediated proteasome
activation, we assayed the e¡ect of PI31 on activated 20S
using Suc-LLVY-AMC as substrate. Increasing amounts of
PI31 were added to serial dilutions of PA28. The kinetics of
activation and inhibition were measured and plotted double
reciprocally in a Lineweaver-Burk plot, as shown in Fig. 6A.
Fig. 5. PI31 does not in£uence the quality of the proteasomal diges-
tion products. A synthetic HepB virus 40-mer polypeptide was di-
gested for 24 h as described in Fig. 3 without proteasome (A) and
with 1 Wg puri¢ed 20S proteasome in the absence (B) and in the
presence (C) of 1.1 Wg PI31.
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Increasing concentrations of PI31 resulted in progressively
ascending slopes. However, there was no systematic change
of the intercept. This is a hallmark of a competitive inhib-
itor.
In order to assess the binding constants for PI31 and PA28,
we ¢tted the rate equation given in the legend of Fig. 6 to the
measured dependency between cleavage rate and inhibitor
concentration at various concentrations of PA28, as is shown
in Fig. 6B. The a⁄nity of PI31 to the 20S proteasome was
estimated to be at least 50 times higher than that of PA28. In
support of this, preincubation of 20S proteasome with PI31 or
with PA28 at room temperature or at 37‡C did not a¡ect the
kinetics of PI31-mediated inhibition of the 20S proteasome
(data not shown). These data indicate that PI31 and PA28
compete with each other for the binding to the 20S protea-
some and that the inhibition of 20S proteasomes by PI31 is
reversible only at high concentrations of PA28.
4. Discussion
Here we used recombinant mouse PI31 to investigate the
in£uence of PI31 on proteasome activity and on PA28-medi-
ated proteasome activation.
Our experiments show that PI31 inhibits the activity of 20S
proteasomes isolated from IFNQ-induced cells and from unin-
duced cells with the same kinetics, indicating that immuno-
subunits do not in£uence the PI31 binding a⁄nity.
Competition experiments with PA28 and PI31 clearly show
that PI31-mediated inhibition of 20S proteasomes is directly
competing with PA28-mediated activation. Kinetic analyses
show that this competition is, due to the clearly distinct
a⁄nities of the two molecules for the 20S proteasome,
strongly biased towards PI31. Only at a concentration that
exceeds the concentration of PI31 at least 50-fold, PA28
would be able to overrule PI31-mediated inhibition of 20S
proteasomes.
Our experiments demonstrate that at high concentrations
the PA28 complex competitively interferes with PI31-mediated
inhibition of 20S proteasomes. Thus, PA28 is in principle able
to replace PI31 from its binding site on the 20S complex.
Since it has been well documented that the PA28 complex
binds the two outer alpha rings of the 20S complex, it is
tempting to speculate that this is also the binding site of
PI31. Structural analysis of PI31 predicts that the N-terminal
region adopts a predominantly helical structure (amino acids
1^149) which is followed by an extended C-terminal region
(amino acids 150^271) which is rich in proline residues. There-
fore, we propose that the N-terminal portion of PI31 binds
the 20S alpha rings, allowing the proline rich region to pro-
trude into the inner cavity of the 20S proteasome. As such,
the C-terminal sequences of the proline rich region (amino
acids 204^271) would reach the inner cavity of the 20S pro-
teasome and thereby either inhibit access to the proteasomal
channel or inhibit the activity of the active centers directly. In
support of this, we ¢nd that the C-terminus of PI31 which
would be of functional importance is highly conserved be-
tween the human and the murine homologue, whereas the
N-terminal part of the proline rich portion (amino acids
Fig. 6. Kinetic analysis of the interaction of PA28 and PI31 with the 20S proteasome. A: Activation kinetics: Double reciprocal plot of the
cleavage rate versus concentration of PA28 at increasing concentrations of PI31 (a, 0.0 WM; b, 0.015 WM; O, 0.075 WM; R, 0.15 WM; E,
0.3WM; F, 1.5 WM). The regression lines reveal increasing slopes but constant intercept indicative for competitive inhibition. For a better visual
inspection of slopes and intercepts the plot is only shown in the range of small 1/S values. B: Inhibition kinetics: Cleavage rate versus concen-
tration of PI31 at four di¡erent concentrations of PA28 was analyzed by using the rate equation
v 
vo  vaPA28Ka
1 PA28
Ka
 PI31
K i
which describes competitive binding of PA28 (with dissociation constant Ka) and PI31 (with dissociation constant Ki) to the proteasome. The
parameters vo and va refer to the maximal cleavage rates of the core 20S proteasome and the PA28-activated proteasome. Fitting this rate
equation to the data (see bold lines) provided the following numerical estimates:
vo 1.49 nmol MCA/min mg proteasome
va 148.4 nmol MCA/min mg proteasome
Ka 44.4 WM
Ki 0.79 WM
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150^203), which would have the role of a spacer in the pro-
posed model, is not as well conserved. Guided by this model,
the di¡erential e¡ects of PI31 on the degradation of the di¡er-
ent short £uorogenic peptides become more conceivable. One
possibility would be that these peptides bypass PI31 with dif-
ferent probabilities, resulting in the measurement of di¡erent
inhibition kinetics. On the other hand, one could propose that
the C-terminus of PI31 preferentially interferes with speci¢c
active centers. For example inhibition of L2, which mediates
trypsin-like activity, might be weaker. This would explain the
residual activities for the Z-LLE-LNa and the Suc-LLVY-
AMC substrate and the less strong inhibition kinetics for
the Bz-VGR-AMC substrate.
Taken together, our results show that PI31 inhibits 20S
activity independent of subunit composition, and overrules
the e¡ect of PA28 on proteasome activation.
One could speculate that competitive PA28 levels could be
achieved at a very local level in speci¢c compartments or by
speci¢c protein modi¢cations. However, this remains to be
shown in further studies using cellular systems.
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